Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.68 +3.4%	$2.82	$0.80 ▼ $4.08	$966.50M	0.85	3.23 million shs	9.32 million shs
ARWR Arrowhead Pharmaceuticals	$15.32 -1.9%	$14.68	$9.57 ▼ $30.41	$2.12B	0.96	1.54 million shs	2.78 million shs
BEAM Beam Therapeutics	$16.76 -1.4%	$17.69	$13.53 ▼ $35.25	$1.69B	2.08	1.49 million shs	2.19 million shs
JANX Janux Therapeutics	$23.60 +3.9%	$26.67	$22.48 ▼ $71.71	$1.40B	2.96	867,159 shs	1.11 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+3.37%	+3.37%	+30.96%	+72.77%	+264.36%
ARWR Arrowhead Pharmaceuticals	-1.92%	-2.67%	+0.07%	+3.51%	-35.02%
BEAM Beam Therapeutics	-1.35%	-1.76%	-2.67%	-28.07%	-27.67%
JANX Janux Therapeutics	+3.87%	-5.22%	-4.72%	-21.18%	-41.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0747 of 5 stars	3.6	2.0	4.0	3.5	0.8	0.6
ARWR Arrowhead Pharmaceuticals	3.5175 of 5 stars	3.4	1.0	3.4	2.4	2.5	0.0
BEAM Beam Therapeutics	3.2058 of 5 stars	4.5	1.0	0.0	2.6	2.5	0.6
JANX Janux Therapeutics	2.2325 of 5 stars	3.5	2.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	83.42% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	185.34% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	190.87% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	303.60% Upside

Current Analyst Ratings Breakdown

Latest AKBA, JANX, BEAM, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$160.18M	6.03	N/A	N/A	($0.23) per share	-16.00
ARWR Arrowhead Pharmaceuticals	$3.55M	595.97	N/A	N/A	$1.54 per share	9.95
BEAM Beam Therapeutics	$63.52M	26.53	N/A	N/A	$8.86 per share	1.89
JANX Janux Therapeutics	$10.59M	131.86	N/A	N/A	$19.49 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.02	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	-463.91%	-9.29%	-8.89%	8/6/2025 (Estimated)

Latest AKBA, JANX, BEAM, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BEAM Beam Therapeutics	N/A	8.81	8.81
JANX Janux Therapeutics	N/A	58.47	58.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
ARWR Arrowhead Pharmaceuticals	62.61%
BEAM Beam Therapeutics	99.68%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
ARWR Arrowhead Pharmaceuticals	4.30%
BEAM Beam Therapeutics	3.50%
JANX Janux Therapeutics	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable

AKBA, JANX, BEAM, and ARWR Headlines

Recent News About These Companies

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Brokerages

June 21 at 4:22 AM | marketbeat.com

Janux Therapeutics Becomes Oversold (JANX)

June 20 at 8:32 AM | nasdaq.com

SG Americas Securities LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

June 20 at 3:28 AM | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 3.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on JANX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Research Analysts Offer Predictions for JANX FY2026 Earnings

June 10, 2025 | marketbeat.com

California State Teachers Retirement System Grows Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

June 8, 2025 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Shares Up 7.9% - Here's What Happened

June 6, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Sees Significant Increase in Short Interest

June 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Takes $2.48 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

June 3, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Wellington Management Group LLP

June 1, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 31, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 31, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLC

May 30, 2025 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2% - Should You Sell?

May 29, 2025 | marketbeat.com

Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 29, 2025 | marketbeat.com

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $22.99 Million Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Woodline Partners LP Buys 251,924 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Rafferty Asset Management LLC Sells 13,522 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 22, 2025 | marketbeat.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts

May 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, JANX, BEAM, and ARWR Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.68 +0.12 (+3.37%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.68 -0.01 (-0.14%)

As of 06/20/2025 07:51 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.32 -0.30 (-1.92%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$15.35 +0.03 (+0.20%)

As of 06/20/2025 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Beam Therapeutics NASDAQ:BEAM

$16.76 -0.23 (-1.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$16.68 -0.09 (-0.51%)

As of 06/20/2025 07:18 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$23.60 +0.88 (+3.87%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.50 -0.10 (-0.42%)

As of 06/20/2025 07:13 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time